Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

ERAS

Erasca Inc

Jun 25 • 04:00PM ET

2.08

Dollar change -0.08
Percentage change -3.70	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IBB SCHA VHT IWN VTWO ITOT SBIO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.84	Insider Own	35.93%	Shs Outstand	259.85M	Perf Week	4.00%
Market Cap	540.49M	Forward P/E	-	EPS next Y	-0.80	Insider Trans	0.09%	Shs Float	166.48M	Perf Month	-19.69%
Income	-126.86M	PEG	-	EPS next Q	-0.18	Inst Own	27.59%	Short Float	8.45%	Perf Quarter	0.48%
Sales	0.00M	P/S	-	EPS this Y	6.86%	Inst Trans	2.02%	Short Ratio	8.67	Perf Half Y	6.67%
Book/sh	1.91	P/B	1.09	EPS next Y	-2.98%	ROA	-30.29%	Short Interest	14.08M	Perf Year	-22.39%
Cash/sh	1.15	P/C	1.82	EPS next 5Y	-	ROE	-37.60%	52W Range	1.51 - 2.97	Perf YTD	-2.35%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-69.36%	ROI	-37.40%	52W High	-29.97%	Beta	1.14
Dividend TTM	-	Quick Ratio	10.14	Sales past 5Y	0.00%	Gross Margin	-	52W Low	37.75%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	10.14	EPS Y/Y TTM	55.02%	Oper. Margin	0.00%	RSI (14)	42.88	Volatility	5.46% 6.31%
Employees	126	Debt/Eq	0.21	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	5.38
Option/Short	Yes / Yes	LT Debt/Eq	0.18	EPS Q/Q	-4.28%	Payout	-	Rel Volume	1.74	Prev Close	2.16
Sales Surprise	-	EPS Surprise	-14.09%	Sales Q/Q	-	Earnings	May 08 AMC	Avg Volume	1.62M	Price	2.08
SMA20	-10.61%	SMA50	-3.08%	SMA200	-1.46%	Trades		Volume	2,828,831	Change	-3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-24	Initiated	CapitalOne	Overweight	$8
Jan-05-24	Downgrade	BofA Securities	Buy → Neutral	$11 → $6
Oct-11-23	Initiated	H.C. Wainwright	Buy	$10
Mar-30-23	Initiated	Mizuho	Buy	$9
Feb-24-23	Initiated	Goldman	Buy	$10
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15

Jun-18-24 12:14PM	Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma (Clinical Trials Arena)
08:00AM	Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma (GlobeNewswire)
Jun-04-24 09:55AM	Should You Buy Erasca, Inc. (ERAS) After Golden Cross? (Zacks)
May-29-24 08:00AM	Erasca to Present at Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 04:05PM	Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:14AM	Loading…
May-17-24 07:14AM	Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs (MT Newswires) +6.49%
05:51AM	Erasca restructures; Novartis moves to complete MorphoSys deal (BioPharma Dive)
05:31AM	Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options (FierceBiotech.com)
04:11AM	Erasca Prices $160 Million Common Stock Offering (MT Newswires)
May-16-24 08:02PM	Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise (GlobeNewswire)
08:00PM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
May-08-24 11:55PM	ERAS Stock Earnings: Erasca Misses EPS for Q1 2024 (InvestorPlace) -8.84%
04:01PM	Erasca Reports First Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
May-07-24 08:00AM	Erasca to Present at the Bank of America Health Care Conference (GlobeNewswire)
Apr-24-24 04:05PM	Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire)
12:00PM	Loading…
Apr-23-24 12:00PM	Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Apr-01-24 04:56PM	Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31AM	Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ... (GuruFocus.com)
Mar-27-24 10:53PM	ERAS Stock Earnings: Erasca Beats EPS for Q4 2023 (InvestorPlace)
08:30PM	Erasca Announces $45 Million Oversubscribed Private Placement Financing (GlobeNewswire)
04:01PM	Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results (GlobeNewswire)
Feb-14-24 08:00AM	Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials (GlobeNewswire)
Feb-01-24 08:00AM	Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 08:00AM	Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 01:34PM	3 Penny Stocks Youll Regret Not Buying Soon: December Edition (InvestorPlace) -5.08%
Dec-11-23 08:00AM	Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma (GlobeNewswire)
Nov-28-23 08:00AM	Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway (GlobeNewswire) -11.38%
Nov-09-23 04:01PM	Erasca Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire) -8.64%
Nov-08-23 08:00AM	Erasca to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-12-23 11:28AM	Insiders Are Betting Millions on These 2 Stocks Heres Why You Might Want to Follow Their Lead (TipRanks)
03:56PM	Loading…
Oct-10-23 03:56PM	Why Shares of Erasca Are Jumping Tuesday (Motley Fool) +13.18%
Sep-19-23 08:00AM	Erasca to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-29-23 08:00AM	Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors (GlobeNewswire)
Aug-10-23 04:01PM	Erasca Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire) +11.92%
Jul-12-23 06:35AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Jun-22-23 04:01PM	Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma (GlobeNewswire) -7.96%
Jun-15-23 06:22AM	Jonathan Lim Spends US$275k On Erasca Stock \ (Simply Wall St.)
Jun-06-23 10:53AM	Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals (Benzinga) -8.18%
Jun-05-23 04:01PM	Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline (GlobeNewswire) +14.19%
Jun-01-23 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 08:00AM	Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor (GlobeNewswire)
May-25-23 05:00PM	Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting (GlobeNewswire) -5.07%
09:01AM	With 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interest (Simply Wall St.)
May-16-23 08:00AM	Erasca Further Strengthens Business Leadership with Two Key Promotions (GlobeNewswire)
May-15-23 04:01PM	Erasca Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
May-02-23 08:00AM	Erasca to Present at the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
May-01-23 08:00AM	Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma (GlobeNewswire)
Apr-26-23 05:00PM	Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma (GlobeNewswire)
Apr-18-23 09:00AM	Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research)
Apr-10-23 08:00AM	Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development (GlobeNewswire) -8.83%
Mar-31-23 06:19AM	Trade Alert: The Co-Founder Of Erasca, Inc. (NASDAQ:ERAS), Jonathan Lim, Has Just Spent US$284k Buying A Few More Shares (Simply Wall St.)
Mar-30-23 04:21AM	6 analyst picks of the day: Walmart stock pops, Fluence upped to Buy \| Pro Recap (Investing.com)
Mar-23-23 04:01PM	Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Mar-14-23 04:31PM	Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting (GlobeNewswire)
Feb-01-23 08:00AM	Erasca to Present at the Guggenheim Oncology Conference 2023 (GlobeNewswire)
Jan-16-23 06:19AM	We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-11-23 03:04PM	11 Best All-Time Low Stocks To Buy Now (Insider Monkey) +8.00%
Jan-04-23 08:00AM	Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-22 08:00AM	Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors (GlobeNewswire)
Dec-17-22 07:28AM	Co-Founder Jonathan Lim Just Bought A Handful Of Shares In Erasca, Inc. (NASDAQ:ERAS) (Simply Wall St.)
Dec-16-22 07:15AM	Erasca, Inc.'s (NASDAQ:ERAS) recent 16% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Dec-13-22 08:00AM	Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors (GlobeNewswire)
Dec-09-22 10:00AM	Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering (Benzinga) -22.30%
07:34AM	Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib (GlobeNewswire)
07:32AM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
Nov-30-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination (GlobeNewswire) +6.34%
Nov-22-22 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-22 09:55AM	Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know (Zacks)
Nov-09-22 04:01PM	Erasca Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire) +16.62%
Oct-20-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination (GlobeNewswire)
Oct-12-22 08:00AM	Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium (GlobeNewswire)
Sep-26-22 08:00AM	Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-09-22 08:31AM	Erasca to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Sep-08-22 11:08AM	Erasca Touts Promising Early Data From Lead Cancer Programs (Benzinga) -11.28%
Sep-07-22 04:05PM	Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials (GlobeNewswire) +6.21%
Aug-24-22 08:00AM	Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors (GlobeNewswire)
Aug-23-22 09:55AM	Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing (Zacks) +5.08%
08:00AM	Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers (GlobeNewswire)
Aug-19-22 09:55AM	Wall Street Analysts See an 111% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks) -5.56%
Aug-11-22 04:05PM	Erasca Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -11.12% +15.35%
Aug-08-22 09:29AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Aug-03-22 09:55AM	Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 244%: Here's is How to Trade (Zacks)
Jul-27-22 06:00PM	Erasca, Inc. (ERAS) Gains But Lags Market: What You Should Know (Zacks)
Jul-21-22 06:00PM	Erasca, Inc. (ERAS) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jul-18-22 06:15PM	Erasca, Inc. (ERAS) Gains As Market Dips: What You Should Know (Zacks) +8.33%
09:55AM	Wall Street Analysts See a 288% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks)
08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination (GlobeNewswire)
Jul-12-22 06:00PM	Erasca, Inc. (ERAS) Stock Moves -0.32%: What You Should Know (Zacks)
Jul-06-22 06:15PM	Erasca, Inc. (ERAS) Outpaces Stock Market Gains: What You Should Know (Zacks) +5.52%
Jun-09-22 09:55AM	Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 362%: Here's is How to Trade (Zacks)
Jun-03-22 09:00AM	Erasca to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire) +13.23%
Jun-02-22 08:00AM	Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers (GlobeNewswire)
May-25-22 08:00AM	Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments (GlobeNewswire)
May-23-22 09:55AM	Erasca, Inc. (ERAS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-12-22 04:01PM	Erasca Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
May-03-22 08:00AM	Erasca to Present at the Bank of America Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-27-22 08:00AM	Erasca Appoints Jean Liu to its Board of Directors (GlobeNewswire)

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 1, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Casdin Alexander W.	Director	May 21 '24	Buy	2.27	80,000	181,920	573,974	May 22 06:57 PM
Lim Jonathan E	Chairman & CEO	Dec 06 '23	Buy	1.72	278,150	478,418	12,899,360	Dec 06 07:41 PM
Start Valerie Denise Harding	Director	Dec 06 '23	Buy	1.85	10,000	18,480	20,000	Dec 08 09:10 AM
Lim Jonathan E	Chairman & CEO	Dec 05 '23	Buy	1.69	721,850	1,217,761	12,899,360	Dec 06 07:41 PM
Casdin Alexander W.	Director	Dec 04 '23	Buy	1.66	30,000	49,785	493,974	Dec 04 06:23 PM
Lim Jonathan E	Chairman & CEO	Oct 05 '23	Buy	2.03	1,000,000	2,026,000	19,456,216	Oct 10 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERAS

Erasca Inc

Upgrade your FINVIZ experience